Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Hyaluronidase

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_2881-2

Definition

Hyaluronidases (HAases) are endoglycosidases that degrade hyaluronic acid (HA). HA is a non-sulfated glycosaminoglycan. Exhaustive digestion of HA with HAase generates tetrasaccharides, whereas limited digestion generates HA fragments, some of which induce angiogenesis.

Characteristics

Six HAase genes are present in the human genome and these occur in two linked triplates. HYAL-1, HYAL-2, and HYAL-3 genes are clustered in the chromosome 3p21.3 locus, whereas HYAL-4, HYAL-P1, and PH20 (which encodes testicular HAase) reside in the chromosome 7q31.3 locus (Stern and Jedrzejas 2006). Based on their pH activity profiles, HAases are divided into two categories. HYAL-1, HYAL-2, and HYAL-3 are considered acidic HAases because they are active at acidic pH. For example, HYAL-1 has a pH optimum around 4.0–4.2, and the enzyme is inactive above pH 5.0. It is normally expressed in serum and urine. On the contrary, PH20 or the testicular HAase is a neutral HAase as it is active at pH 7.0...

Keywords

Hyaluronic Acid Forster Resonance Energy Transfer Hyaluronidase Activity Inhibit Prostate Cancer Cell Multicellular Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, Lokeshwar VB (2011) Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res 71(12):4085–4095. doi:10.1158/0008-5472.CAN-10-4610CrossRefPubMedPubMedCentralGoogle Scholar
  2. Isoyama T, Thwaites D, Selzer MG, Carey RI, Barbucci R, Lokeshwar VB (2006) Differential selectivity of hyaluronidase inhibitors toward acidic and basic hyaluronidases. Glycobiology 16(1):11–21. doi:10.1093/glycob/cwj036CrossRefPubMedGoogle Scholar
  3. Lokeshwar VB, Schroeder GL, Carey RI, Soloway MS, Iida N (2002) Regulation of hyaluronidase activity by alternative mRNA splicing. J Biol Chem 277(37):33654–33663. doi:10.1074/jbc.M203821200CrossRefPubMedGoogle Scholar
  4. Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL (2005) HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res 65(17):7782–7789. doi:10.1158/0008-5472.CAN-05-1022Google Scholar
  5. Lokeshwar VB, Estrella V, Lopez L, Kramer M, Gomez P, Soloway MS, Lokeshwar BL (2006) HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res 66(23):11219–11227. doi:10.1158/0008-5472.CAN-06-1121CrossRefPubMedGoogle Scholar
  6. Lokeshwar VB, Gomez P, Kramer M, Knapp J, McCornack MA, Lopez LE, Fregien N, Dhir N, Scherer S, Klumpp DJ, Manoharan M, Soloway MS, Lokeshwar BL (2008) Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem 283(43):29215–29227. doi:10.1074/jbc.M801101200CrossRefPubMedPubMedCentralGoogle Scholar
  7. Lokeshwar VB, Mirza S, Jordan A (2014) Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res 123:35–65. doi:10.1016/B978-0-12-800092-2.00002-2CrossRefPubMedGoogle Scholar
  8. McAtee CO, Barycki JJ, Simpson MA (2014) Emerging roles for hyaluronidase in cancer metastasis and therapy. Adv Cancer Res 123:1–34. doi:10.1016/B978-0-12-800092-2.00001-0CrossRefPubMedGoogle Scholar
  9. Stern R, Jedrzejas MJ (2006) Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev 106(3):818–839. doi:10.1021/cr050247kCrossRefPubMedPubMedCentralGoogle Scholar
  10. Yang R, Pfutze K, Zucknick M, Sutter C, Wappenschmidt B, Marme F, Qu B, Cuk K, Engel C, Schott S, Schneeweiss A, Brenner H, Claus R, Plass C, Bugert P, Hoth M, Sohn C, Schmutzler R, Bartram CR, Burwinkel B (2015) DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood. Int J Cancer 136(8):1845–1855. doi:10.1002/ijc.29205CrossRefPubMedGoogle Scholar

See Also

  1. (2012) Biomarkers. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 408–409. doi:10.1007/978-3-642-16483-5_6601Google Scholar
  2. (2012) Targeted therapy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3610. doi:10.1007/978-3-642-16483-5_5677Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of UrologyUniversity of Miami – Miller School of MedicineMiamiUSA
  2. 2.Department of Biochemistry and Molecular BiologyMedical College of Georgia; Augusta UniversityAugustaUSA